Aytu BioPharma Files 8-K Report
Ticker: AYTU · Form: 8-K · Filed: Dec 4, 2024 · CIK: 1385818
| Field | Detail |
|---|---|
| Company | Aytu Biopharma, Inc (AYTU) |
| Form Type | 8-K |
| Filed Date | Dec 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, filing
Related Tickers: AYTU
TL;DR
AYTU filed a standard 8-K, no major news.
AI Summary
On December 3, 2024, Aytu BioPharma, Inc. filed an 8-K report to disclose information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing serves as a routine update and does not appear to contain new material information that would immediately impact the company's stock price.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material events or financial information that would indicate increased risk.
Key Players & Entities
- AYTU BIOPHARMA, INC (company) — Registrant
- 0001385818 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
- 470883144 (company) — IRS Number
- DE (company) — State of Incorporation
- 0630 (company) — Fiscal Year End
- 001-38247 (company) — SEC File Number
- 241524573 (company) — Film Number
- 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237 (company) — Business Address
- AYTU BIOSCIENCE, INC (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing by Aytu BioPharma, Inc.?
The primary purpose of this 8-K filing is to disclose information under Regulation FD and to file financial statements and exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on December 4, 2024, with the date of the earliest event reported being December 3, 2024.
What is Aytu BioPharma, Inc.'s state of incorporation and IRS Employer Identification Number?
Aytu BioPharma, Inc. is incorporated in Delaware and its IRS Employer Identification Number is 47-0883144.
Has Aytu BioPharma, Inc. operated under any former company names?
Yes, Aytu BioPharma, Inc. has operated under the former names AYTU BIOSCIENCE, INC. (with a name change date of 20150609) and Rosewind CORP (with a name change date of 20070110).
What is the business address of Aytu BioPharma, Inc. as listed in the filing?
The business address of Aytu BioPharma, Inc. is 7900 E. Union Avenue, Suite 920, Denver, CO 80237.
Filing Stats: 660 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-12-03 21:30:15
Key Financial Figures
- $0.0001 — ch Registered Common Stock , par value $0.0001 per share AYTU The NASDAQ Stock Mar
Filing Documents
- aytu20241203_8k.htm (8-K) — 25KB
- ex_753794.htm (EX-99.1) — 60KB
- logo01.jpg (GRAPHIC) — 4KB
- 0001437749-24-036630.txt ( ) — 242KB
- aytu-20241203.xsd (EX-101.SCH) — 3KB
- aytu-20241203_def.xml (EX-101.DEF) — 12KB
- aytu-20241203_lab.xml (EX-101.LAB) — 15KB
- aytu-20241203_pre.xml (EX-101.PRE) — 12KB
- aytu20241203_8k_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On December 3, 2024, Aytu BioPharma, Inc., a Delaware corporation (the "Company" or "Aytu"), announced that the settlement it had previously disclosed of certain derivative claims in the action entitled Witmer v. Armistice Capital, LLC et al is scheduled for a court approval hearing on January 13, 2025 in the Delaware Chancery Court. The Notice of Pendency of Derivative Action, Proposed Settlement of Derivative Action, Proposed Agreement of Settlement and Release, and Settlement Hearing (the "Notice") is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Notice is also available for review on the Investor Relations section of the Company's website at https://investors.aytubio.com/more-resources#MoreResources. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, which are furnished herewith pursuant to and relate to this Item 7.01, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities of Section 18 of the Exchange Act. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 hereto shall not be incorporated by reference into any filing or other document filed by the Company with the SEC pursuant to the Securities Act of 1933, as amended, the rules and regulations of the SEC thereunder, the Exchange Act, or the rules and regulations of the SEC thereunder except as shall be expressly set forth by specific reference in such filing or document. .
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Notice of Pendency of Derivative Action, Proposed Settlement of Derivative Action, Proposed Agreement of Settlement and Release, and Settlement Hearing 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AYTU BIOPHARMA, INC. Date: December 3, 2024 By: /s/ Ryan Selhorn Ryan Selhorn Chief Financial Officer